<unk> , known as FibroSure in the US, is a patented biomarker test that uses the results of six blood serum tests to generate a score that is correlated with the degree of liver damage in people with a variety of liver diseases.<unk>  has the same prognostic value as a liver biopsy.<unk>  has been evaluated in relation to liver biopsy (the current reference standard in liver disease assessment) in a large number of patients with hepatitis C, hepatitis B, alcoholic liver disease, Non-alcoholic fatty liver disease and in the general population. By 2008 it had been used in over 350,000 patients.<unk>  has been validated for the initial diagnosis of fibrosis, but also for the monitoring of patients.[citation needed]  In 2006, the French National Authority for Health recommended the use of<unk>  as a first-line assessment tool for fibrosis with untreated chronic hepatitis C.
FibroTest
Thrombophilia CT
Fibrin degradation product
International Society on Thrombosis and Haemostasis bleeding scale
Prothrombin time
D-dimer
Impedance phlebography
Activated clotting time